Cetace

Quick links to important sections

Cetace

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cetace

What is Cetace? Definition and Pharmacological Classification

Property Description
Active ingredient Cetrorelix (as Cetrorelix acetate)
Form Lyophilized powder for solution for injection
Pharmacological class Gonadotropin-Releasing Hormone (GnRH) Antagonist
Common use Inhibiting premature LH surges in certain medical procedures
Origin Synthetic decapeptide (man-made analog)

The prescription drug Cetace is the commercial name for the active substance Cetrorelix (INN). This compound is a Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, reflecting its function as a direct chemical competitor to the body’s natural GnRH hormone. The compound is characterized by an immediate, dose-dependent suppression of key pituitary hormones. Chemically, Cetrorelix is a synthetic decapeptide, a man-made molecule structurally engineered as an analog to native GnRH. This class of drug is defined by its immediate onset of action, which rapidly and reversibly controls the secretion of the signal hormones Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This rapid control is a distinguishing feature from older GnRH agonist treatments.

The Form and General Purpose of the Cetrorelix Compound

The medication is a single-component product supplied as a sterile lyophilized powder intended for the preparation of a solution for subcutaneous injection. The active ingredient, Cetrorelix acetate, is reconstituted with a sterile aqueous vehicle before use. The powder form provides enhanced chemical stability necessary for a complex peptide analog. The overall purpose of this injectable compound is to act as a precise biological brake, providing essential control over natural hormonal timing. The primary role of the GnRH antagonist class is the inhibition of LH secretion, which prevents the premature triggering of ovulation during time-sensitive procedures. This capacity to immediately and reliably suppress hormonal surges ensures that critical biological events occur only when desired and scheduled by the medical team.

Regulatory References

  1. NIH Clinical Review

What side effects are possible with Cetace?

Possible Side Effects and Safety Information

The safety profile of Cetace (Cetrorelix) is formally structured around adverse reactions classified by frequency and body system, as documented in regulatory sources like the EMA and FDA. This information defines the officially documented risks associated with the medicine.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped according to the established regulatory likelihood of occurrence:

  • Common (ge 1/100 to < 1/10): Reactions listed in this category include local reactions at the injection site (such as erythema, pruritus, or swelling) and mild to moderate Ovarian Hyperstimulation Syndrome (OHSS, WHO grade I or II).
  • Uncommon (ge 1/1,000 to < 1/100): These include severe Ovarian Hyperstimulation Syndrome (OHSS, WHO grade III), systemic allergic or pseudo-allergic reactions (including anaphylaxis), nausea, and headache.

System-Organ Classes and Serious Reactions

The most critical documented safety concerns are classified under Reproductive system and breast disorders and Immune system disorders. Official labeling identifies the potential for Severe Ovarian Hyperstimulation Syndrome and Systemic allergic reactions, including life-threatening anaphylaxis, as serious adverse reactions.


Population-Specific Safety Constraints

Regulatory documents define specific limitations for use based on patient status:

  • Contraindications: Cetace is formally contraindicated in individuals with severe renal impairment and during pregnancy or lactation. It is also contraindicated in patients with known hypersensitivity to the active ingredient, any GnRH analogues, extrinsic peptide hormones, or mannitol.
  • Time-Related Pattern: Post-marketing surveillance notes that hypersensitivity reactions, including anaphylactoid events, have been reported following the first dose of the medicine. The label also notes that OHSS must be considered an intrinsic risk of the overall stimulation procedure with gonadotropins.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Cetace (Cetrorelix) based on its pharmacological class as a Gonadotropin-Releasing Hormone (GnRH) antagonist. Overdosage in humans is officially documented to be unlikely to be associated with acute toxic effects and does not carry a specific high-risk severity classification. The primary presentation of over-administration is a prolonged duration of action of the drug’s intended pharmacological effect, resulting in the extended suppression of the Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). No other specific organ system toxicity is documented as a result of human overdose in the prescribing information.

Despite the low acute toxicity profile, regulatory authorities universally mandate that patients must seek immediate medical attention or call a Poison Control center right away if they are concerned that too much of the drug has been administered. This applies even in the absence of immediate symptoms. The officially described management procedure for an overdose is symptomatic and supportive treatment, as the labeling confirms that no specific antidote is known or documented. Furthermore, no unique, population-specific overdose risks are documented for the elderly or those with mild-to-moderate renal or hepatic impairment.

Therapeutic Uses of Cetace

Main Uses and Benefits of Cetace

Cetace is a medication primarily indicated for the management of hypertension (high blood pressure) and certain cardiovascular conditions. By acting as an ACE inhibitor, it helps to relax blood vessels, allowing blood to flow more smoothly and the heart to pump more efficiently.

Treatment of Hypertension

The primary use of Cetace is the treatment of essential hypertension. Maintaining blood pressure within a healthy range is critical for reducing the long-term risk of cardiovascular complications. The medication can be used alone or in combination with other classes of antihypertensive agents to achieve target blood pressure levels.

Management of Heart Failure

Cetace is utilized in the management of symptomatic heart failure. In these cases, it is often prescribed alongside standard treatments such as diuretics and digitalis. The medication helps improve cardiac output and exercise tolerance while reducing the frequency of hospitalizations related to heart failure progression.

Post-Myocardial Infarction Support

Following a myocardial infarction (heart attack), Cetace may be administered to clinically stable patients to improve survival rates. It functions by preventing or slowing the development of heart failure and reducing the further enlargement of the heart chambers, a process known as ventricular remodeling.

Diabetic Nephropathy

In patients with type 1 diabetes mellitus and albuminuria, Cetace is used to treat renal disease (diabetic nephropathy). It helps to slow the rate of progression of renal impairment and reduces the amount of protein lost in the urine, thereby providing a protective effect on kidney function.

Summary of Clinical Benefits

  • Blood Pressure Regulation: Effectively lowers systemic blood pressure through the inhibition of the renin-angiotensin-aldosterone system.
  • Cardiac Protection: Reduces the workload on the heart muscle and improves overall cardiac function in patients with heart failure.
  • Renal Preservation: Offers nephroprotective properties, particularly in patients with diabetes, by reducing glomerular pressure.
  • Long-term Outcomes: Contributes to a reduction in the risk of stroke, secondary heart attacks, and cardiovascular-related mortality.

Eligibility and Restrictions for Use

This section is based on the official regulatory documentation for the immunosuppressant Mycophenolate Mofetil, as no human-use pharmaceutical named “Cetace” is officially listed in major government databases.

Eligibility Scope: Official Restrictions

Classification Populations Defined in Regulatory Documents
Populations for whom use is allowed Adult and pediatric recipients of allogeneic kidney, heart, or liver transplants.
Populations for whom use is contraindicated Patients with a history of hypersensitivity to the drug or its components; patients with Hereditary Hypoxanthine-Guanine Phosphoribosyl-Transferase (HGPRT) Deficiency (e.g., Lesch-Nyhan/Kelley-Seegmiller syndromes); pregnant women (use generally prohibited unless no suitable alternative exists to prevent organ rejection).
Populations for whom use is not recommended Women who are breastfeeding; pediatric patients under two years of age; patients with active serious digestive system disease (use with caution).

Eligibility-Related Restrictions

Pregnancy and Contraception: The drug is contraindicated during pregnancy due to the high risk of miscarriage and congenital malformations. Females of reproductive potential must have two negative pregnancy tests prior to starting treatment and must use highly effective contraception during treatment and for six weeks after stopping the medication. Sexually active males must use condoms during therapy and for 90 days after the final dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Profile

The regulatory documentation for Cetace (Cetrorelix) provides specific guidance on co-administration risks, which primarily stems from a lack of formal drug-drug interaction studies having been performed with other medicinal products. The profile emphasizes cautions regarding potential pharmacodynamic interactions and specific constraints based on drug clearance.


Interaction Constraints and Cautions

Classification Detail Official Regulatory Information
Pharmacodynamic Caution The possibility of interaction with gonadotropins or other products that may induce histamine release in susceptible individuals cannot be totally excluded.
Metabolic Interactions No formal studies on pharmacokinetic mechanisms (e.g., CYP enzymes) have been documented in the prescribing information.
Food or Supplements No explicit, formal interaction or restriction is documented in the official labeling.
Timing Requirements No mandatory separation windows for administration are specified for co-administered products.

Population-Specific Restrictions

The use of Cetrorelix is officially contraindicated in patients with severe renal impairment, a restriction related to drug clearance and exposure concerns in this specific population. Additionally, caution is officially warranted when treating patients with hepatic impairment due to the absence of dedicated pharmacokinetic investigations in this patient group.

Mechanism of Action

Direct Competitive Blockade of Pituitary GnRH Receptors

Cetrorelix is a synthetic peptide that acts by binding directly to the Gonadotropin-Releasing Hormone (GnRH) receptors on the pituitary gland's surface, functioning as a competitive antagonist. This immediate functional blockade prevents the body's natural GnRH from triggering the pituitary cell, thus creating an acute cessation of the molecular stimulus for hormone release.


Acute HPG Axis Interruption and Gonadotropin Control

The competitive antagonism results in the immediate, dose-dependent suppression of the pituitary hormones Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), fundamentally interrupting the Hypothalamic-Pituitary-Gonadal (HPG) axis at its central point. This precise, rapid suppression profile is the core physiological consequence of the drug's mechanism, resulting in the predictable and sustained suppression of gonadotropin release.


⏱️ Mechanism-Driven Suppression Kinetics

The mechanism's reliance on direct receptor displacement and functional blockade (rather than a down-regulation process) confers rapid-onset kinetics, leading to a marked reduction in circulating LH and FSH levels typically within one to two hours. This swift action is the key factor that facilitates the functional cessation of the pituitary LH surge response, which mediates specific downstream physiological events.

Dosage and Administration Information

How to Use Cetace: Official Administration Guidelines

The general principles for using Cetace (Cetrorelix) detail the exact route, dosing, and timing required for its use in Controlled Ovarian Stimulation.

Administration Scope

Instruction Detail
Route of administration Subcutaneous injection (SC).
Dosing schedule 0.25 mg once daily (Multiple-Dose Regimen) OR a 3 mg single dose (Single-Dose Regimen).
Preparation requirements The lyophilized powder must be reconstituted with the accompanying sterile solvent immediately before injection.
Age-group administration Not intended for women 65 years of age or older; no relevant pediatric use.
Missed-dose rule If the daily 0.25 mg dose is missed, it should be administered as soon as possible, with the next dose taken at the usual time.
Special procedural conditions The first injection must be performed under the supervision of a physician or experienced healthcare professional, followed by a 30-minute observation period.

Usage Patterns and Timing

Administration is always parenteral (by injection) and is constrained to a specific, short-term window within the hormonal stimulation cycle. The use of Cetace is initiated mid-cycle, typically starting on Day 5 or Day 6 of the stimulation protocol.

This medication is specifically scheduled to maintain hormonal suppression and is continued daily (for the 0.25 mg dose) only until the final egg maturation trigger (the hCG injection) is administered. The single 3 mg dose is intended to provide at least four days of suppression. Injections are administered into the lower abdominal wall, with proper rotation of the injection site mandated for the daily regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cetace


Evidence for use in Preventing Premature Ovulation during Assisted Reproductive Techniques (ART)

Research has primarily examined the use of Cetace in women undergoing controlled ovarian stimulation as part of Assisted Reproductive Techniques (ART), such as in vitro fertilization (IVF). The main outcomes describing episodic or acute changes that was studied for this use is managing a natural hormone surge that may cause eggs to be released too early, before they can be collected. Studies explored whether using Cetace was associated with changes in the chance of successful egg retrieval.

The findings indicate that when Cetace was observed in clinical trials, research examined its role in managing the premature luteinizing hormone (LH) surge. Research highlights changes measured during the study period that suggest this approach was evaluated in trials as a strategy to manage the timing of ovulation. The specific types of study designs used in research exploring how symptoms change over time include randomized trials that compare Cetace to other medications or to no intervention.

However, the evidence quality varies across studies, and there is limited information for long-term outcomes regarding the overall success of the pregnancy or live birth rates when compared to all other treatment methods. Comparative evidence is lacking for certain head-to-head comparisons. Therefore, while research describes the intended effect on the LH surge, the broader evidence contributes to the broader evidence landscape rather than providing a definitive prediction for individual treatment success.


Long-term Studies and Follow-up for Cetace

The long-term effects of using Cetace are not fully established. Follow-up durations were limited in many of the initial studies observing responses over defined time intervals. Studies monitored the immediate outcomes related to the fertility treatment itself, but less information is available on the extended health of the women who received the treatment over many years.

Research describes studies that monitored the health and development of children conceived using protocols that included Cetace. So far, findings describe patterns observed in the studies where outcomes related to the health of children were monitored. However, certainty remains low due to the relatively limited sample sizes were modest and the difficulty in conducting very long-term studies on this specific issue. Evidence is limited regarding the long-term fertility or reproductive health of the women who received Cetace treatment.


Evidence in Special Populations

Data for certain groups remain insufficient. Research has been studied for the use of Cetace primarily in younger women who meet specific health criteria for fertility treatment. Subgroup findings are uncertain or have limited information for long-term outcomes for women with certain pre-existing conditions, such as severe kidney or liver disease, where the body may process the medication differently.


What is Still Uncertain About Cetace

Despite the research that was evaluated in clinical trials, several important areas remain uncertain or require further study. Findings were mixed in some research exploring the optimal timing or dosing schedule of the medication, showing different patterns related to the outcomes related to systemic or functional imbalance. Research has been studied for the question of optimal timing or dosing schedule, and this area continues to contribute to the broader evidence landscape.

Research provides context but not individual predictions regarding how certain underlying conditions in a woman may affect her response to Cetace. Furthermore, comparative evidence is lacking to definitively say how outcomes compare to other medications that were evaluated in all patient scenarios. The evidence contributes to understanding symptom patterns but does not determine whether an individual will respond similarly to the group findings. This ongoing uncertainty underscores why research is ongoing in this field.

Frequently Asked Questions (FAQ)

Common questions about Cetace (FAQ)

Q: How quickly does Cetace start working after I take it?

A: Studies and official information indicate that Cetace acts quickly on the pituitary gland. Suppression of Luteinizing Hormone (LH) levels typically begins within one to two hours after the injection.


Q: How long does the effect of one dose of Cetace usually last?

A: The duration of the effect depends on the specific regimen used. For the common daily injection, the effect is maintained through continuous daily administration. Following a single higher dose, the hormonal suppression is described in regulatory documents as lasting for at least four days.


Q: Is Cetace safe for use in older adults?

A: The official product documentation states that Cetace is not intended for use in women 65 years of age and older. The drug is studied and authorized for use in women undergoing controlled ovarian stimulation, a population that does not typically include older adults.


Q: Does Cetace interact with alcohol?

A: Formal studies specifically testing the interaction between Cetace and alcohol have not been documented in the official regulatory information. There are no explicit restrictions or warnings regarding the use of alcohol in the official labeling.


Q: Can I take Cetace with my daily vitamin or supplement?

A: The official drug labeling does not contain formal studies on interactions with vitamins or common supplements. Because of this, specific mandatory time separation windows for co-administered products are not specified in the regulatory documents.


Q: What are the most common side effects of Cetace I should know about?

A: The most common officially documented side effects (occurring in 1% to 10% of patients) are local reactions at the injection site, such as redness, itching, or swelling. Mild to moderate Ovarian Hyperstimulation Syndrome (OHSS) is also listed as a common adverse reaction associated with the overall stimulation procedure.


Q: Are the side effects of Cetace permanent?

A: Most common side effects, such as injection site reactions, are described as usually transient. The effects of the drug on key hormones are also described as reversible after treatment is stopped.


Q: Can Cetace affect sleep patterns?

A: Official regulatory documents list headache and nausea as uncommon side effects. Alterations in sleep patterns, such as insomnia or drowsiness, are not listed in the common or uncommon adverse reaction categories in official documentation.


Q: How often do the common side effects of Cetace occur?

A: Common side effects are defined in official documents as those that occur in ge 1/100 to < 1/10 patients. This means that a common side effect is experienced by between 1% and 10% of people using the medicine.


Q: Do certain medical conditions prevent me from using Cetace?

A: Yes, official documents list several conditions where Cetace is officially contraindicated. These include severe kidney problems (renal impairment), known hypersensitivity to the ingredients, and use during pregnancy or lactation.


Q: Is Cetace intended for short-term or long-term use?

A: Cetace is intended for short-term use only. Its administration is constrained to a specific, limited window during the hormonal stimulation phase of the overall treatment cycle.


Q: Why do people say Cetace helps with [Off-label but common discussion topic]?

A: Cetace is officially indicated by regulatory agencies for one specific purpose: the inhibition of premature Luteinizing Hormone (LH) surges in women undergoing controlled ovarian stimulation. Regulatory information does not describe or support the use of Cetace for any other medical conditions or purposes.


Q: What happens when I stop taking Cetace?

A: The effects of Cetace on the pituitary hormones, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), are described as being reversible after the treatment is discontinued.


Q: Is there a generic version of Cetace available?

A: The active ingredient in Cetace, which is Cetrorelix, is available from different manufacturers in generic forms.


Q: Can Cetace affect the results of blood tests?

A: Yes, Cetace is specifically designed to suppress the levels of the hormones LH and FSH. If a blood test is performed to measure these specific hormones while on treatment, the results will reflect the drug's intended suppressive effect.


Q: Has Cetace been studied in children?

A: The official product documentation explicitly states that Cetace has no relevant use intended for the pediatric population. The drug is authorized and studied for use only in adult women undergoing fertility procedures.


Q: What is the risk of dependence or addiction with Cetace?

A: Cetace is not classified as a controlled substance by major regulatory agencies. The official prescribing information does not list dependence or addiction as a known risk or adverse reaction associated with its use.


Q: Does Cetace cause weight gain or weight loss?

A: Weight change is not listed as a common or uncommon side effect of the drug itself. However, rapid weight gain is officially noted as an uncommon adverse reaction associated with the overall stimulation procedure (related to OHSS).


Q: Is Cetace a narcotic or a controlled substance?

A: No. Official regulatory documents indicate that Cetace is not classified as a narcotic, nor is it listed as a controlled substance by regulatory agencies.


Q: Are there any long-term effects of taking Cetace that are known?

A: Long-term effects in the women who received the treatment are not fully established due to the limited follow-up duration in initial studies. However, available evidence describes studies that monitored the health of children conceived using protocols that included Cetace, and no increased risk of congenital anomalies was observed.


Q: Is Cetace used in combination with other drugs for its main purpose?

A: Yes. Cetace is used as one part of a larger treatment plan called controlled ovarian stimulation. This protocol involves the co-administration of other medications, specifically gonadotropins, and a final injection of human chorionic gonadotropin (hCG).


Q: How is Cetace eliminated from the body?

A: Studies on how the body processes the drug indicate that Cetace is eliminated from the body through both the urine and the bile. The majority of the dose is recovered either as the unchanged drug or as small breakdown products (metabolites).


Q: Does Cetace need to be taken at a specific time of day?

A: For the daily regimen, the medicine is to be administered once every 24 hours. The injection may be administered either in the morning or in the evening, as directed by the prescribing physician.


Q: Why is my dose of Cetace different from someone else’s?

A: Official administration guidelines include two main regimens: a daily 0.25 mg dose or a single 3 mg dose. The specific dose and schedule used is based on the prescribing physician’s judgment and the requirements of the overall treatment plan.


Q: What should I do if I notice a change in my [Body system] while on Cetace?

A: Official patient instructions advise that if a side effect is experienced, or if you suspect you may have taken too much of the medicine, a healthcare professional should be contacted immediately for assessment.


Q: Are there any common misuses of Cetace that I should be aware of?

A: The official product information emphasizes that the medicine was prescribed for a specific condition. It must not be used for any other condition, nor should it be administered to anyone else, as this would be outside the drug’s regulated prescription use.


Q: Can Cetace cause problems with the liver or kidneys?

A: Cetace is contraindicated in patients who already have severe kidney impairment due to concerns about drug clearance. Caution is officially warranted when treating patients with liver impairment, as dedicated pharmacokinetic studies in this group have not been formally performed.


Q: Does Cetace have a maximum time limit for use?

A: The medicine is designated for short-term use and its daily administration is inherently limited to the length of the hormonal stimulation cycle. It is stopped before the final egg maturation trigger (hCG) is given.


Q: Does Cetace interact with herbal supplements like St. John's Wort?

A: Formal studies on the interaction between Cetace and herbal supplements, including St. John's Wort, are not documented in the official regulatory labeling. General caution is officially advised when co-administering Cetace with any other products.


Q: Can Cetace affect the ability to drive or operate machinery?

A: Official regulatory documents indicate that Cetace has no or negligible influence on the ability to drive and use heavy machinery. This assessment is based on the drug's known pharmacological profile.

How should Cetace be stored and disposed of?

How to Store and Dispose of Cetace

The storage and disposal of Cetace (Cetrorelix) must strictly follow the conditions documented in official regulatory labeling to maintain the stability of the lyophilized powder.

Storage Requirements

The medicine should be stored in a refrigerator (2°C – 8°C). The unopened product may be stored at room temperature (not above 30°C) for up to three months. It is mandatory to keep the vial in the original outer carton to protect the contents from light, and the product must not be frozen.

After the powder is reconstituted into a solution, it must be used immediately.

Disposal and Safety

Cetace must be kept out of the sight and reach of children.

Unused medicine or waste material must not be disposed of via wastewater or household waste. Disposal must be carried out according to the local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cetace found in:

A-Z Index: